17 citations
,
October 2006 in “Molecular and Cellular Endocrinology” The L457(3.43)R mutation in the human lutropin receptor causes increased activity and hormone insensitivity, leading to precocious puberty.
July 2025 in “Annals of Medicine” Gestrinone pellets may help reduce pelvic pain in endometriosis safely.
36 citations
,
July 2005 in “Journal of Neuroendocrinology” Blocking certain brain processes reduces mating behavior in female rats.
Targeting the PGI2 pathway may help heal diabetic foot ulcers.
25 citations
,
July 2006 in “Journal of Neurochemistry” Progesterone affects GABAA receptor function by altering δ subunit levels.
164 citations
,
January 2003 in “Drugs” 1 citations
,
April 2013 in “The FASEB Journal” 3α‐OH‐DHP is essential for reducing nerve activity related to blood pressure control during pregnancy.
19 citations
,
March 2010 in “Steroids” Certain progesterone derivatives can inhibit enzymes and reduce androgenic activity, potentially affecting prostate growth.
44 citations
,
February 2009 in “Pain” Progesterone reduces spinal reflex activity by increasing certain GABA(A) receptor subtypes.
151 citations
,
December 2004 in “Neuropharmacology” Progesterone reduces anxiety without needing progesterone receptors.
1 citations
,
November 1975 in “PubMed” GRF is not safe for tubal occlusion.
1 citations
,
September 2024 in “Frontiers in Cell and Developmental Biology” PRF is better than PRP for endometrial repair.
15 citations
,
April 2008 in “Steroids” The more lipophilic the progesterone derivative, the better it binds to androgen receptors and has antiandrogenic effects.
39 citations
,
March 2008 in “Journal of biological chemistry/The Journal of biological chemistry” GLI2 increases follistatin production in human skin cells.
14 citations
,
March 2017 in “Brain research” Progesterone and its byproducts control a specific receptor in the brain independently of progesterone receptors, affecting conditions related to the menstrual cycle.
13 citations
,
May 2007 in “Journal of Endocrinology” Synthetic 19-norprogestins promote bone cell growth and function through their non-phenolic metabolites.
5 citations
,
May 2018 in “European journal of pharmacology” Fesoterodine is effective and safe for elderly patients with overactive bladder.
1 citations
,
August 2011 in “Planta Medica” Bimatoprost effectively promotes hair growth.
67 citations
,
October 2005 in “Annals of Oncology” Fulvestrant is a well-tolerated new treatment for advanced breast cancer that may delay chemotherapy.
28 citations
,
November 2009 in “European Journal of Neuroscience” Progesterone and allopregnanolone increase glycine release in rat brain cells.
2 citations
,
January 2023 in “PubMed” Targeting FGF5 could help treat prostate cancer.
September 2023 in “bioRxiv (Cold Spring Harbor Laboratory)” FOL-026 peptide can help repair blood vessels and promote growth, offering potential treatment for vascular diseases.
46 citations
,
December 2001 in “Journal of Endocrinology/Journal of endocrinology” FLRG and follistatin have different roles in wound healing.
18 citations
,
March 2002 in “The journal of investigative dermatology/Journal of investigative dermatology” Estrogen increases blood vessel growth factor production, while testosterone blocks this increase.
44 citations
,
June 2017 in “The EMBO Journal” LPA3 signaling in the uterus is crucial for placental formation and fetal development.
41 citations
,
February 2012 in “Journal of Neuroendocrinology” Allopregnanolone helps control oxytocin levels during pregnancy to prevent preterm labor.
20 citations
,
January 2003 in “Chemical and Pharmaceutical Bulletin” The new progesterone derivatives effectively inhibit 5α-reductase and bind to the androgen receptor.
1 citations
,
March 2009 in “The Journal of Urology” Combination therapy with fesoterodine and doxazosin improves bladder function and delays BPH progression.
103 citations
,
June 2018 in “International Journal of Molecular Sciences” FGF signaling is a promising target for developing treatments for wounds, metabolic diseases, and cancer.
April 2025 in “Frontiers in Pharmacology” Canagliflozin helps overcome progestin resistance in certain endometrial cancer cells.